公开(公告)号：US20240102094A1

公开(公告)日：2024-03-28

申请号：US18255524

申请日：2021-12-03

Applicant: AMGEN INC.

Inventor： Daniel C. ELLWANGER ,  Ian N. FOLTZ ,  Samuel A. HASSON

IPC: C12Q1/6883 ,  C12Q1/6874 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q1/6874 ,  G01N33/6896 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2800/2821 ,  G01N2800/52

Abstract: The present invention provides a method of treating a disease or conditions associated with a dysfunction of TREM2 in a human patient, such as Alzheimer's disease, comprising administering to the patient a TREM2 agonist. In another aspect, the invention provides a method of assaying a biological sample taken from a patient having Alzheimer's for biomarkers to determine potential benefit or if the disease has an increased probability of responding to treatment with a TREM2 agonist.